TP53 and lymphoma: On the other hand, in the large, “real‐world evidence” retrospective study by the US Lymphoma CAR T Consortium [37], PFS was inferior in patients with high‐risk MIPI (HR 3.82; p < 0.001), Ki‐67% ≥ 50% (HR 3.02; p = 0.007), TP53 mutation or deletion (HR 1.98; p = 0.008), complex karyotype (HR 2.23; p = 0.005) and blastoid/pleomorphic variant (HR 1.61; p = 0.036).